Interferon-beta and disability progression in relapsing-remitting multiple sclerosis

Clinical Neurology and Neurosurgery ◽

10.1016/j.clineuro.2013.09.024 ◽

2013 ◽

Vol 115 ◽

pp. S65-S69 ◽

Author(s):

Jelena Drulovic ◽

Jelena Kostic ◽

Sarlota Mesaros ◽

Irena Dujmovic Basuroski ◽

Nebojsa Stojsavljevic ◽

...

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Disability Progression ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Interferon-beta 1A and disability progression in relapsing-remitting multiple sclerosis: 9-year follow-up study

Journal of the Neurological Sciences ◽

10.1016/j.jns.2015.08.1063 ◽

2015 ◽

Vol 357 ◽

pp. e302

Author(s):

J. Drulovic ◽

V. Martinovic ◽

J. Kostic ◽

S. Mesaros ◽

I. Dujmovic ◽

...

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Disability Progression ◽

Follow Up Study ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Interferon beta-1b therapy in relapsing-remitting multiple sclerosis: Study design and preliminary results

Electroencephalography and Clinical Neurophysiology ◽

10.1016/s0013-4694(97)88414-7 ◽

1997 ◽

Vol 103 (1) ◽

pp. 99

Author(s):

G Salemi

Keyword(s):

Multiple Sclerosis ◽

Study Design ◽

Interferon Beta ◽

Preliminary Results ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Predictors of long term disability progression in patients with relapsing remitting multiple sclerosis

10.26226/morressier.5b719e445aff74008ae4ce73 ◽

2018 ◽

Author(s):

Valentina Ignatova

Keyword(s):

Multiple Sclerosis ◽

Disability Progression ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Parity and disability progression in relapsing–remitting multiple sclerosis

Journal of Neurology ◽

10.1007/s00415-020-10093-1 ◽

2020 ◽

Vol 267 (12) ◽

pp. 3753-3762

Author(s):

Anat Achiron ◽

◽

Alon Ben-David ◽

Michael Gurevich ◽

David Magalashvili ◽

...

Keyword(s):

Multiple Sclerosis ◽

Disability Progression ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

PNR1: COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF INTERFERON BETA-IB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN POLAND (2-YEARS PERSPECTIVE)

Value in Health ◽

10.1016/s1098-3015(11)70789-6 ◽

2000 ◽

Vol 3 (5) ◽

pp. 362-363

Author(s):

E Orlewska ◽

P Mierzejewski ◽

A Czlonkowska

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Interferon Beta ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Interferon Beta Use and Disability Prevention in Relapsing-Remitting Multiple Sclerosis

JAMA Neurology ◽

10.1001/jamaneurol.2013.1017 ◽

2013 ◽

Vol 70 (2) ◽

pp. 248 ◽

Author(s):

Benjamin M. Greenberg ◽

Laura Balcer ◽

Peter A. Calabresi ◽

Bruce Cree ◽

Anne Cross ◽

...

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Disability Prevention ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

5-31-07 Interferon beta 1a in the treatment of relapsing/remitting multiple sclerosis

Journal of the Neurological Sciences ◽

10.1016/s0022-510x(97)86469-6 ◽

1997 ◽

Vol 150 ◽

pp. S321

Author(s):

R. Ljapcev ◽

L. Gogovska ◽

M. Tanovska

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

PND44 Assessing Variations in Transitions in Employment in Relapsing-Remitting Multiple Sclerosis Patients Treated With Either Laquinimod, Interferon Beta 1-a or Placebo: Expoloratory Evidence From the United States Substudy of Bravo

Value in Health ◽

10.1016/j.jval.2012.03.803 ◽

2012 ◽

Vol 15 (4) ◽

pp. A149

Author(s):

C.A. Carroll ◽

M.A. Oleen-Burkey

Keyword(s):

United States ◽

Multiple Sclerosis ◽

Interferon Beta ◽

The United States ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Multiple Sclerosis Patients ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

How does alemtuzumab compare with interferon beta 1a in people with relapsing-remitting multiple sclerosis?

Cochrane Clinical Answers ◽

10.1002/cca.1996 ◽

2018 ◽

Author(s):

Jane Burch ◽

Loredana La Mantia

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-Effectiveness of Daclizumab Versus Interferon Beta-1A in the Treatment of Patients with Relapsing-Remitting Multiple Sclerosis in the United States

Value in Health ◽

10.1016/j.jval.2018.04.1400 ◽

2018 ◽

Vol 21 ◽

pp. S206

Author(s):

D Rao ◽

E Heidari ◽

KM Kamal ◽

AA Dashputre

Keyword(s):

United States ◽

Multiple Sclerosis ◽

Cost Effectiveness ◽

Interferon Beta ◽

The United States ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text